Johnson & Johnson Innovation, New York State and New York Genome Center Collaborate to Launch JLABS in New York City
Called JLABS @ NYC, 30,000-square foot facility will hold capacity for up to 30 life science startups focused on biotech, pharmaceutical, medical device and consumer health
New collaboration receives $17 million in New York State funding and will support growth of healthcare solutions in the region by providing development and commercialization resources for emerging life science companies
NEW YORK CITY, Jan. 9, 2017 — Johnson & Johnson Innovation LLC, New York State and the New York Genome Center today announced a collaboration to launch a new JLABS in New York City. Called JLABS @ NYC, the 30,000-square foot facility will be located at the New York Genome Center (NYGC) in SoHo and will open in 2018. The project is receiving $17 million in New York State funding. The site will be open to biotech, pharmaceutical, medical device and consumer health companies. A QuickFire Challenge seeking companies working in these areas, particularly startups working on cross-sector solutions to prevent, intercept or cure diseases, will be launched by Johnson & Johnson Innovation, with the winner(s) eligible for one year of residency at JLABS @ NYC.
“The ever-evolving life science sector is discovering solutions to the most pressing problems of our time, helping to cure disease and save lives around the world,” said Governor Cuomo. “New York is poised to be a global leader in this industry, and the new, vital incubator JLABS will be the catalyst that pushes our state into the forefront of this exciting field. I look forward to working with Johnson & Johnson and the New York Genome Center to build momentum in the life science industry and establish New York as the home of discoveries that will drive the economy create a better future for all.”
Download the PDF for the full press release.